Search research articles
Contact Us
Filters
Showing results (161-170 of 252) with videos related to
Page
of 26
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
June 4, 2017
Role of hepatectomy in gastric cancer with multiple liver-limited metastases
Hiromichi Shirasu, Takahiro Tsushima, Masahiro Kawahira, et al.
The Oncologist
|
June 7, 2023
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, et al.
Clinical Colorectal Cancer
|
February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Takayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2011
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
Kohei Shitara, Takashi Ura, Keitaro Matsuo, et al.
BMC Cancer
|
October 30, 2021
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, et al.
Journal of Human Genetics
|
December 9, 2022
Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients
Hiroyuki Matsubayashi, Akiko Todaka, Takeshi Kawakami, et al.
International Journal of Clinical Oncology
|
June 23, 2018
Phase II study of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> in Japanese patients with advanced gastric cancer
Yosuke Kito, Nozomu Machida, Sadayuki Kawai, et al.
Molecular and Clinical Oncology
|
December 2, 2015
Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin
Yoshiki Horie, Kentaro Yamazaki, Taro Funakoshi, et al.
International Journal of Clinical Oncology
|
September 1, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, et al.
BMC Cancer
|
August 22, 2023
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 252) with videos related to
Sort By:
Page
of 26
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
June 4, 2017
Role of hepatectomy in gastric cancer with multiple liver-limited metastases
Hiromichi Shirasu, Takahiro Tsushima, Masahiro Kawahira, et al.
The Oncologist
|
June 7, 2023
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, et al.
Clinical Colorectal Cancer
|
February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Takayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2011
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
Kohei Shitara, Takashi Ura, Keitaro Matsuo, et al.
BMC Cancer
|
October 30, 2021
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, et al.
Journal of Human Genetics
|
December 9, 2022
Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients
Hiroyuki Matsubayashi, Akiko Todaka, Takeshi Kawakami, et al.
International Journal of Clinical Oncology
|
June 23, 2018
Phase II study of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> in Japanese patients with advanced gastric cancer
Yosuke Kito, Nozomu Machida, Sadayuki Kawai, et al.
Molecular and Clinical Oncology
|
December 2, 2015
Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin
Yoshiki Horie, Kentaro Yamazaki, Taro Funakoshi, et al.
International Journal of Clinical Oncology
|
September 1, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, et al.
BMC Cancer
|
August 22, 2023
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, et al.
Page
of 26